Author: Vitaliy Dadalyan

The Real Value in Novavax Goes Beyond the Coronavirus

Investors have been trading biotech stocks on the news all year. It’s been like watching a slow motion horse race play out. Novavax (NASDAQ:NVAX) stock is up over 2,500% since the beginning of the year. And if the race was simply about stock performance, NVAX would be running away from the field. Source: Ascannio/Shutterstock.com As of this writing, Moderna (NASDAQ:MRNA) is up approximately 260%. This is impressive and the stock has received a lot of attention from investors. But simply in terms of stock performance, it’s far behind Novavax. Johnson & Johnson (NYSE:JNJ), which is considered to be the current favorite to get a vaccine to market, is basically flat for the year. Pfizer (NYSE:PFE) stock is actually down for the year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips However, despite the gamification that takes place in the market, this race has serious consequences. Just having a vaccine available is not enough....